The international clinical trial, which is expected to involve 350-400 patients across 11 countries, will study the cancer stem cell inhibitor defactinib.
The international clinical trial, which is expected to involve 350-400 patients across 11 countries, will study the cancer stem cell inhibitor defactinib.